30-Oct-2025 7:30 AM CST - Business Wire Alpha Cognition (Nasdaq: ACOG) to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, November 13, 2025 Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its third quarter 2025 financial results and provide a business update on Thursday, November 13, 2025, at 4:30 p.m. ET, after market close. The company will issue a press release detailing its third quarter financial results and business highlights on that date. The financial
28-Aug-2025 12:00 PM CST - Business Wire Alpha Cognition Inc. (Nasdaq: ACOG) Announces Participation in Key September Investor Conferences Alpha Cognition Inc. (Nasdaq: ACOG), a commercial-stage biopharmaceutical company dedicated to developing innovative treatments for neurodegenerative diseases, today announced that Chief Executive Officer Michael McFadden will present at two prominent healthcare investor conferences this September. Cantor Global Healthcare Conference 2025 Date/Time: Friday, September 5, 7:00 a.m. ET H.C. Wainwright & Co. Healthcare Conference 2025 Date/
14-Aug-2025 7:30 AM CST - Business Wire Alpha Cognition Inc. Reports Second Quarter 2025 Financial Results and Provides Operational Update Alpha Cognition Inc. (Nasdaq: ACOG) (Alpha Cognition or the Company) today announced its financial results for the second quarter ended June 30, 2025. The initial ZUNVEYL launch has been met with strong interest from both healthcare providers and patients. Early adoption in nursing homes and by geriatric specialists has created a solid foundation for future growth, said Michael McFadden, Chief Executive Officer of Alpha Cogn
4-Aug-2025 7:30 AM CST - Business Wire Alpha Cognition to Report Second Quarter 2025 Financial Results and Operating Overview Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will release financial results for the second quarter on August 14, 2025 after close of market. Following the release, management will host a conference call to review financial and operating results. Conference Call Information: To participate in the conference call, please use the dial-
15-May-2025 7:30 AM CST - Business Wire Alpha Cognition Inc. Reports First Quarter 2025 Financial Results and Operating Overview Alpha Cognition Inc. (Nasdaq: ACOG) (Alpha Cognition, or the Company) today announced its financial results for the first quarter ended March 31, 2025. We closed the quarter on a strong note, launching ZUNVEYL to the long-term care market, said Michael McFadden, Chief Executive Officer. We feel that the company is operating at a high level and are on schedule and within budget on all of our launch plans. Early market feedback on ZUNVEYL util
1-May-2025 7:30 AM CST - Business Wire Alpha Cognition to Report First Quarter 2025 Financial Results and Operating Overview Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today will announce financial results for the first quarter ended March 31, 2025 on May 15, 2025 after close of market. Following the release, management will host a conference call to review financial and operating results. Conference Call Information: To participate in the conference call, please use the dial-
31-Mar-2025 7:30 AM CST - Business Wire Alpha Cognition Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview Alpha Cognition Inc. (Nasdaq: ACOG) (Alpha Cognition, or the Company) today announced its financial results for the fourth quarter and full year ended December 31, 2024. We closed 2024 on a strong note, securing capital to support the ZUNVEYL commercial launch and assembling an experienced leadership team, said Michael McFadden, Chief Executive Officer. In early 2025, we completed the manufacturing of the initial commercial supply of ZUNVEYL.
19-Mar-2025 3:30 PM CST - Business Wire Alpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating Overview Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will release financial results for the fourth quarter and full year ended December 31, 2024 on March 31, 2025 after close of market. Following the release, management will host a conference call to review financial and operating results. Conference Call Information: To participate in the
6-Jan-2025 7:30 AM CST - Business Wire Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimers Long-Term Care Market During Investor Update Call Alpha Cognition Inc. (Nasdaq: ACOG) (Alpha Cognition, or the Company), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced it will host an investor update call on Tuesday, January 28th, 2025 at 4pm EST to present its commercial launch strategy for ZUNVEYL (benzgalantamine), an FDA-approved treatment for mild-to-moderate Alzheimers disease (AD). The call will focus on the companys plans t
30-Oct-2025 7:30 AM CST - Business Wire Alpha Cognition (Nasdaq: ACOG) to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, November 13, 2025 Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its third quarter 2025 financial results and provide a business update on Thursday, November 13, 2025, at 4:30 p.m. ET, after market close. The company will issue a press release detailing its third quarter financial results and business highlights on that date. The financial
28-Aug-2025 12:00 PM CST - Business Wire Alpha Cognition Inc. (Nasdaq: ACOG) Announces Participation in Key September Investor Conferences Alpha Cognition Inc. (Nasdaq: ACOG), a commercial-stage biopharmaceutical company dedicated to developing innovative treatments for neurodegenerative diseases, today announced that Chief Executive Officer Michael McFadden will present at two prominent healthcare investor conferences this September. Cantor Global Healthcare Conference 2025 Date/Time: Friday, September 5, 7:00 a.m. ET H.C. Wainwright & Co. Healthcare Conference 2025 Date/
14-Aug-2025 7:30 AM CST - Business Wire Alpha Cognition Inc. Reports Second Quarter 2025 Financial Results and Provides Operational Update Alpha Cognition Inc. (Nasdaq: ACOG) (Alpha Cognition or the Company) today announced its financial results for the second quarter ended June 30, 2025. The initial ZUNVEYL launch has been met with strong interest from both healthcare providers and patients. Early adoption in nursing homes and by geriatric specialists has created a solid foundation for future growth, said Michael McFadden, Chief Executive Officer of Alpha Cogn
4-Aug-2025 7:30 AM CST - Business Wire Alpha Cognition to Report Second Quarter 2025 Financial Results and Operating Overview Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will release financial results for the second quarter on August 14, 2025 after close of market. Following the release, management will host a conference call to review financial and operating results. Conference Call Information: To participate in the conference call, please use the dial-
15-May-2025 7:30 AM CST - Business Wire Alpha Cognition Inc. Reports First Quarter 2025 Financial Results and Operating Overview Alpha Cognition Inc. (Nasdaq: ACOG) (Alpha Cognition, or the Company) today announced its financial results for the first quarter ended March 31, 2025. We closed the quarter on a strong note, launching ZUNVEYL to the long-term care market, said Michael McFadden, Chief Executive Officer. We feel that the company is operating at a high level and are on schedule and within budget on all of our launch plans. Early market feedback on ZUNVEYL util
1-May-2025 7:30 AM CST - Business Wire Alpha Cognition to Report First Quarter 2025 Financial Results and Operating Overview Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today will announce financial results for the first quarter ended March 31, 2025 on May 15, 2025 after close of market. Following the release, management will host a conference call to review financial and operating results. Conference Call Information: To participate in the conference call, please use the dial-
31-Mar-2025 7:30 AM CST - Business Wire Alpha Cognition Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview Alpha Cognition Inc. (Nasdaq: ACOG) (Alpha Cognition, or the Company) today announced its financial results for the fourth quarter and full year ended December 31, 2024. We closed 2024 on a strong note, securing capital to support the ZUNVEYL commercial launch and assembling an experienced leadership team, said Michael McFadden, Chief Executive Officer. In early 2025, we completed the manufacturing of the initial commercial supply of ZUNVEYL.
19-Mar-2025 3:30 PM CST - Business Wire Alpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating Overview Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will release financial results for the fourth quarter and full year ended December 31, 2024 on March 31, 2025 after close of market. Following the release, management will host a conference call to review financial and operating results. Conference Call Information: To participate in the
6-Jan-2025 7:30 AM CST - Business Wire Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimers Long-Term Care Market During Investor Update Call Alpha Cognition Inc. (Nasdaq: ACOG) (Alpha Cognition, or the Company), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced it will host an investor update call on Tuesday, January 28th, 2025 at 4pm EST to present its commercial launch strategy for ZUNVEYL (benzgalantamine), an FDA-approved treatment for mild-to-moderate Alzheimers disease (AD). The call will focus on the companys plans t
